![]() ![]() de Hingh, Catharina Hospital, Eindhoven, the Netherlands Wim P. Pelz, University of Wuerzburg, Wuerzburg and Pompiliu Piso, University Medical Center Regensburg, Regensburg, Germany.Ĭeelen, University Hospital, Ghent Kurt Van Der Speeten, Ziekenhuis Oost-Limburg, Genk, Belgium Joerg O. Two thousand two hundred ninety-eight patients from 16 specialized units underwent CRS for PMP. Treatment-related mortality was 2% and major operative complications occurred in 24% of patients. The median survival rate was 196 months (16.3 years) and the median progression-free survival rate was 98 months (8.2 years), with 10- and 15-year survival rates of 63% and 59%, respectively. Multivariate analysis identified prior chemotherapy treatment ( P <. 001), peritoneal mucinous carcinomatosis (PMCA) histopathologic subtype ( P <. 001), major postoperative complications ( P =. 013), debulking surgery (completeness of cytoreduction, 2 or 3 P <.Ġ08), high peritoneal cancer index ( P =. 030) as independent predictors for a poorer progression-free survival. 006), major postoperative complications ( P <. 001), prior chemotherapy treatment ( P =. 001), and PMCA histopathologic subtype ( P <. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |